TriSalus Life Sciences (TLSI) issues Q2 2025 business update and results

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. filed a current report to note that on August 12, 2025 it issued a press release providing a business update and announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is treated as furnished, not filed, under securities laws, which limits its use in certain types of investor lawsuits and in other company filings unless specifically incorporated by reference.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001826667FALSE00018266672025-08-122025-08-120001826667us-gaap:CommonStockMember2025-08-122025-08-120001826667us-gaap:WarrantMember2025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

TRISALUS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-39813			85-3009869
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)
6272 W 91st Ave, Westminster, Colorado						80031
(Address of Principal Executive Offices)						(Zip Code)

(888) 321-5212

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.0001 par value			TLSI			Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share			TLSIW			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Conditions.

On August 12, 2025, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filings.

Item 9.01						Financial Statements and Exhibits.
(d)
Exhibit Number						Description
99.1						Press Release dated August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 12, 2025			TriSalus Life Sciences, Inc.
			By:			/s/ David Patience
						Name:			David Patience
						Title:			Chief Financial Officer

FAQ

What did TriSalus Life Sciences (TLSI) report in this 8-K filing?

TriSalus Life Sciences, Inc. reported that it issued a press release on August 12, 2025 providing a business update and announcing financial results for the quarter ended June 30, 2025.

Which period’s results does the TriSalus (TLSI) press release cover?

The press release announced by TriSalus Life Sciences covers the company’s financial results for the quarter ended June 30, 2025.

How is the TriSalus (TLSI) press release treated under SEC rules?

The information in Item 2.02, including Exhibit 99.1, is furnished rather than filed, so it is not subject to the liabilities of Section 18 of the Exchange Act and is not automatically incorporated into other SEC filings.

Where can investors find the TriSalus (TLSI) business update and earnings details?

The detailed business update and quarterly financial results are contained in the press release that is included as Exhibit 99.1 to this report.

Who signed the TriSalus Life Sciences (TLSI) 8-K report?

The report was signed on behalf of TriSalus Life Sciences, Inc. by David Patience, the company’s Chief Financial Officer, dated August 12, 2025.

What exhibits are included with this TriSalus (TLSI) 8-K?

The report includes Exhibit 99.1, a press release dated August 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.